The intrinsic coagulation pathway plays a dominant role in driving hypercoagulability in ANCA-associated vasculitis.

"Conflict-of-interest disclosure: H.t.C. and H.M.H.S. received funding for research from 10.13039/100004326Bayer and 10.13039/100004319Pfizer, and are stakeholders in Coagulation Profile. H.t.C. is a consultant for Alveron and has served on advisory boards for Bayer, Pfizer, Daiichi, Leo, Gilead, Novostia, Galapagos, Viatris and AstraZeneca. C.P.R. is a co-inventor of a patent describing use of low anticoagulant heparins in sepsis and owned by Maastricht University, and is a scientific consultant for Matisse Pharmaceuticals and Annexin Pharmaceuticals. S.A.M.E.G.T. participated in TMA expert meetings and received travel/speaker fees from Alexion Pharmaceuticals Inc (AstraZeneca). The remaining authors declare no competing financial interests."

"H.t.C. and H.M.H.S. received grant support from the Netherlands Heart Foundation (CVON2014-09, Reappraisal of Atrial Fibrillation: Interaction between HyperCoagulability, Electrical Remodeling, and Vascular Destabilization in the Progression of Atrial Fibrillation (RACE V). H.t.C. was supported by a fellowship of the Gutenberg University Mainz. M.N. was supported by the 10.13039/100002129Dutch Heart Foundation. S.A.M.E.G.T. received funding from the 10.13039/501100002997Dutch Kidney Foundation (ie, Nierstichting; 23OK1056)."